US Broker Ratings

Charles River Laboratories Inte (CRL) Stock Analysis: Evaluating a 14.48% Potential Upside

Charles River Laboratories International, Inc. (NYSE: CRL), a key player in the healthcare sector specializing in diagnostics and research, offers intriguing prospects for individual investors. With a market capitalization of..

Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring a 12.68% Potential Upside in the Healthcare Giant

Gilead Sciences, Inc. (NASDAQ: GILD), a formidable player in the healthcare sector, has long been a staple for investors seeking exposure to the biopharmaceutical space. With a robust market capitalization..

Waystar Holding Corp. (WAY) Stock Analysis: A 53% Upside Potential Drives Investor Interest

Investors with an eye on the healthcare sector could find a compelling opportunity in Waystar Holding Corp. (NASDAQ: WAY). With its position in the health information services industry, Waystar is..

Qiagen N.V. (QGEN) Investor Outlook: Analyzing Potential Upside of Over 35% in the Diagnostics Sector

For investors with an eye on the healthcare sector, Qiagen N.V. (NYSE: QGEN) presents a compelling opportunity. Based in the Netherlands, Qiagen operates in the diagnostics and research industry, offering..

Boston Scientific Corporation (BSX) Stock Analysis: A Promising 60.48% Potential Upside for Investors

Boston Scientific Corporation (NYSE: BSX), a prominent player in the healthcare sector, is capturing investor attention with a compelling potential upside of 60.48%. As a leading developer and manufacturer of..

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Navigating Biotech Volatility with a 29.44% Upside Potential

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a prominent player in the biotechnology sector, presents a fascinating opportunity for investors navigating the volatile healthcare market. With a market capitalization of $12.35 billion..

Centene Corporation (CNC) Stock Analysis: Navigating Healthcare with a 22.97% Potential Upside

Centene Corporation (NYSE: CNC), a prominent player in the healthcare plans industry, offers a compelling opportunity for investors seeking exposure to the healthcare sector. With a market capitalization of $17.27..

Option Care Health, Inc. (OPCH) Stock Analysis: A 45% Upside Potential with Strong Buy Ratings

Option Care Health, Inc. (NASDAQ: OPCH), a prominent player in the healthcare sector, has caught the eye of investors with its promising market potential and robust analyst ratings. Known for..

Regencell Bioscience Holdings (RGC) Stock Analysis: Navigating the Volatility of a $15.23 Billion TCM Innovator

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is a notable player in the healthcare sector, focusing on the development and commercialization of Traditional Chinese Medicine (TCM) for neurocognitive disorders. Headquartered in..

Genmab A/S (GMAB) Stock Analysis: Unveiling a 35% Upside Potential in the Biotech Sector

Genmab A/S (NASDAQ: GMAB), a prominent player in the biotechnology sector, is drawing significant attention from investors due to its robust growth prospects and extensive portfolio of antibody-based products. With..

Alcon Inc. (ALC) Stock Analysis: Unveiling a 27.83% Potential Upside in the Eye Care Giant

Alcon Inc. (ALC), a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry, is drawing investor attention with its promising potential upside of 27.83%. Based..

Solventum Corporation (SOLV) Stock Analysis: Unlocking a 36% Upside Potential in Healthcare

Investors seeking opportunities amid the dynamic landscape of the healthcare sector might find Solventum Corporation (SOLV) an intriguing prospect. Despite recent market fluctuations, the company stands out with a potential..

Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Highlights 22% Upside Potential Amidst Robust Revenue Growth

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has been catching the eye of investors in the biotechnology sector, particularly those with a focus on companies engaged in cutting-edge healthcare solutions. With a..

Regeneron Pharmaceuticals, Inc. (REGN)

⚠️ No article content returned.

..

AptarGroup, Inc. (ATR) Stock Analysis: Exploring a 29% Potential Upside with Strong Analyst Ratings

AptarGroup, Inc. (NYSE: ATR) stands as a formidable player in the healthcare sector, more specifically within the medical instruments and supplies industry. With its headquarters in Crystal Lake, Illinois, AptarGroup..

Globus Medical, Inc. (GMED) Stock Analysis: Unveiling a 25% Potential Upside in the Healthcare Sector

Globus Medical, Inc. (NYSE: GMED), a key player in the healthcare sector, is capturing investor attention with a promising 25.21% potential upside, as highlighted by the average target price from..

Teleflex Incorporated (TFX) Stock Analysis: Navigating a 10.54% Potential Upside in the Medical Device Sector

Teleflex Incorporated (NYSE: TFX), a key player in the medical instruments and supplies industry, offers a unique investment opportunity amidst the complexities of the healthcare sector. With a market capitalization..

Waters Corporation (WAT) Stock Analysis: Unpacking a 29.22% Potential Upside for Investors

Waters Corporation (NYSE: WAT) stands as a formidable player in the Healthcare sector, specifically within the Diagnostics & Research industry. With a market capitalization of $29.85 billion, the company has..

Tenet Healthcare Corporation (THC) Stock Analysis: Exploring a 38.91% Potential Upside for Savvy Investors

Tenet Healthcare Corporation (NYSE: THC) stands out in the healthcare sector with a robust market capitalization of $16.54 billion. As a key player in the medical care facilities industry, Tenet..

Revolution Medicines, Inc. (RVMD) Stock Analysis: Unpacking a 34.89% Potential Upside in Precision Oncology

Revolution Medicines, Inc. (NASDAQ: RVMD) stands at the forefront of the biotechnology sector, carving a niche in the precision oncology space with its innovative approach to targeting RAS-addicted cancers. This..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds